HER2/ErbB2 Monoklonaler Antikörper

HER2/ErbB2 Monoklonal Antikörper für IF

Wirt / Isotyp

Maus / IgG2b

Getestete Reaktivität

human

Anwendung

IF

Konjugation

CoraLite®594 Fluorescent Dye

CloneNo.

1B12A7

Kat-Nr. : CL594-60311

Synonyme

CD340, ERBB2, HER 2, HER 2/neu, HER2, HER2/ErbB2, MLN 19, MLN19, NEU, NGL, p185, p185erbB2, Proto oncogene c ErbB 2, Proto oncogene Neu, TKR1

---

Galerie der Validierungsdaten

• 

  IF Staining of human breast cancer using CL594-60311

  Immunofluorescent analysis of (4% PFA) fixed human breast cancer tissue using CoraLite®594 HER2/ErbB2 antibody (CL594-60311, Clone: 1B12A7 ) at dilution of 1:100.

---

Geprüfte Anwendungen

• Erfolgreiche Detektion in IF: humanes Mammakarzinomgewebe

Empfohlene Verdünnung

• Immunfluoreszenz (IF): IF : 1:50-1:500

It is recommended that this reagent should be titrated in each testing system to obtain optimal results.

Sample-dependent, check data in validation data gallery

Produktinformation

CL594-60311 bindet in IF HER2/ErbB2 und zeigt Reaktivität mit human

• Getestete Reaktivität: human
• Wirt / Isotyp: Maus / IgG2b
• Klonalität: Monoklonal
• Typ: Antikörper
• Immunogen: HER2/ErbB2 fusion protein Ag16463
• Vollständiger Name: v-erb-b2 erythroblastic leukemia viral oncogene homolog 2, neuro/glioblastoma derived oncogene homolog (avian)
• Berechnetes Molekulargewicht: 1255 aa, 138 kDa
• GenBank-Zugangsnummer: BC156755
• Gene symbol: ERBB2
• Gene ID (NCBI): 2064
• Konjugation: CoraLite®594 Fluorescent Dye
• Excitation/Emission maxima wavelengths: 588 nm / 604 nm
• Form: Liquid
• Reinigungsmethode: Protein-A-Reinigung
• Lagerungspuffer: BS mit 50% Glyzerin, 0,05% Proclin300, 0,5% BSA, pH 7,3.
• Lagerungsbedingungen: Bei -20°C lagern. Vor Licht schützen. Nach dem Versand ein Jahr stabil. Aliquotieren ist bei -20^oC Lagerung nicht notwendig. 20ul Größen enthalten 0,1% BSA.

Hintergrundinformationen

HER2, also known as ErbB2 and Neu, is a 185-kDa transmembrane glycoprotein that is a member of the epidermal growth factor (EGF) receptor family of receptor tyrosine kinases. It has no ligand binding domain of its own and therefore cannot bind growth factors. However, it does bind tightly to other ligand-bound EGF receptor family members to form a heterodimer, stabilizing ligand binding and enhancing kinase-mediated activation of downstream signalling pathways, such as those involving mitogen-activated protein kinase and phosphatidylinositol-3 kinase. Amplification and/or overexpression of HER2 have been reported in numerous cancers, including breast and ovarian tumors. HER2 is a therapeutic target for the treatment of breast cancer and other carcinomas.